BriaCell Therapeutics Corp

(BCT:CA)

By |

Profile

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer, including the first off-the-shelf personalized approach to immunotherapy. The company recently achieved proof-of-concept in a Phase I/IIa clinical trial for its lead product candidate, Bria-IMT, in patients with advanced breast cancer. The trail was being conducted along with the co-development of BriaDX, the Company's companion diagnostic test. Currently, BriaCell is conducting an FDA approved combination study of Bria-IMT with pembrolizumab - Keytruda; manufactured by Merck & Company Inc or ipilimumab - Yervoy manufactured by Bristol-Myers Squibb company for patients with advanced breast cancer.

Contact Information

Website: www.briacell.com
Email: jwerbes@shaw.ca
Main Phone: +1 604 921-1810
Address: 235 - 15th Street
Address 2: Suite 300
State: BC
City / Town: West Vancouver
Country: CAN
Postal Code: V7T 2X1

Issuer Information

Exchange: CDX
CEO: William Williams
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)
$ 0.095 $ 0.005 (5.56%)
Last Price 0.095 Change $ 0.005 Change % 5.56 Tick N/A
Bid 0.09 Bid Size 42,000.00 Ask 0.095 Ask Size 23,000.00
Open N/A High N/A Low N/A Prev Close 0.09
Last Trade Volume 30,000 52 Wk Hi 0.20 52 Wk Low 0.09
Market Cap 15.4 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 162,154,529.00 EPS (TTM) -0.04 PE Ratio N/A Exchange TSXV

News